ERBB2 and breast carcinoma: Butein reduced viabilities of almost all breast cancer cell lines tested, whereas it did not affect viabilities of luminal HER2+ HCC-1419, HCC-2218 and SKBR-3 breast cancer cells (Figure 1B).